A joint partnership between DSM and Evonik will see the development of algae-based omega-3 fatty acid products.

In a bid to meet demand for omega-3 fatty acids the two companies will utilise naturally occurring marine algae using sustainable, biotechnological processes based on natural, non-marine resources.

The proposed products will be high value, natural and sustainable alternatives to fish oil, which is in limited supply. The companies will work together to harness both their areas of expertise in order to work on the development of products and explore opportunities for commercialisation. Evonik has long been focussed on industrial amino acid biotechnology executing large-volume processes, which DSM specialises in the cultivation of marine organisms and long-established biotechnology capabilities in development and operations.

Thanks to the algae-based omega-3 fatty acid products the animal industry will be able to keep up with increasing demand without endangering fish stocks and will contribute to healthy and sustainable animal nutrition. DSM and Evonik are looking to contribute to a more sustainable aquaculture industry by using algae.

The partnership comes amid news that DSM second quarter turnover was up 12 per cent on a year ago at almost €2bn, boosted by currency effects and volume growth. Net profit rose 25 per cent to €99m.